Business Context and Reporting Period
Company: InspireMD, Inc. (Nasdaq: NSPR)
Filing Type: Form 8-K (Current Report)
Reporting Date: July 30, 2025 (Earliest event reported)
Principal Executive Offices: Miami, Florida
This filing reports the entry into a material definitive agreement for a private placement offering, the full exercise of Series I warrants, and changes to the Board of Directors.
Key Financial Metrics and Capital Events
- Private Placement Offering:
- Securities Issued: 6,791,380 shares of Common Stock and pre-funded warrants to purchase up to 9,764,804 shares.
- Offering Price: $2.42 per Private Placement Share; $2.4199 per Pre-Funded Warrant.
- Gross Proceeds: Approximately $40.1 million (before fees and expenses).
- Expected Closing: On or about August 1, 2025.
- Placement Fee: 6.0% of aggregate gross proceeds plus up to $75,000 in expense reimbursement.
- Series I Warrant Exercise:
- Volume: Full exercise of 12.9 million Series I warrants.
- Conversion: Converted into 2,352,393 common shares and 10,561,685 pre-funded warrants.
- Gross Proceeds: Approximately $17.9 million.
- Exercise Price: $1.3827 per common share; $1.3826 per pre-funded warrant.
Note: This filing does not provide revenue, profit, cash flow, margins, or debt metrics for the reporting period.
Material Changes and Corporate Governance
Board of Directors Changes
- Board Expansion: Board size increased from 7 to 8 directors.
- New Appointment: Mr. Raymond W. Cohen appointed as a Class 3 director effective on the Closing Date of the offering.
- Compensation: Granted stock options and restricted stock with an aggregate value of approximately $180,000 (75% restricted stock, 25% options).
- Vesting: One-year anniversary of grant, subject to continued service, with accelerated vesting if not re-elected or nominated in 2026.
- Background: Former CEO of Axonics, Inc. (sold to Boston Scientific in Nov 2024); currently serves on boards of Kestra Medical Technologies, Nalu Medical, and Archimedes Vascular.
- Resignations: Directors Kathryn Arnold and Thomas Kester notified the Company they will not stand for re-election at the 2026 annual meeting and expect to resign on or about December 31, 2025. Resignations are voluntary and not due to disagreements.
Guidance, Risks, and Contingencies
- Closing Contingencies: The Private Placement Offering is expected to close on or about August 1, 2025, but is subject to customary conditions. Failure to satisfy conditions may prevent closing.
- Registration Rights: The Company must file a resale registration statement within 20 days of signing and have it declared effective within 45 days (or 90 days if reviewed by the SEC). Failure to do so triggers liquidated damages.
- Lock-up Restrictions: For six months following closing, the Company is restricted from entering into "variable rate transactions" and must abide by customary standstill restrictions.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the offering closing and future operations, which are subject to risks and uncertainties.
Investor Verification Checklist
- Verify the actual closing date of the Private Placement Offering (expected August 1, 2025) and confirm receipt of the $40.1 million in gross proceeds.
- Confirm the filing and effectiveness of the resale registration statement required under the Registration Rights Agreement.
- Monitor the impact of the new share issuance (approx. 16.5 million new shares/warrants) on existing shareholder dilution.
- Review the Company's use of the combined proceeds ($40.1M from placement + $17.9M from warrant exercise) for operational liquidity or debt reduction.
- Track the transition of Board committee roles following the expected December 2025 resignations of Directors Arnold and Kester.